CTSG and chronic granulomatous disease: The lentiviral vector used in the trial contains a chimeric promoter (CHIM) consisting of the 5′ minimal flanking region of the myeloid human genes CTSG (Cathepsin G) and FES (c-Fes) and preferentially drives high transgene expression in mature granulocytes and monocytes, the affected cells in CGD [12].